Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LK-SC001
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
LiveKidney Begins Trial for LK-SC001 in Lupus with First Patient Enrolled
Details : LK-SC001, a proprietary formulation of UC-MSCs designed to improve kidney function. It is being evaluated for the treatment of lupus nephritis patients.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 06, 2025
Lead Product(s) : LK-SC001
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UC-Mesenchymal Stem Cell
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Medical University of South Carolina | Galilee CBR
Deal Size : Inapplicable
Deal Type : Inapplicable
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
Details : UC-Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : UC-Mesenchymal Stem Cell
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Medical University of South Carolina | Galilee CBR
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
